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Abstract
Background: To reduce the likelihood of complications in persons with type 2 diabetes, it is
critical to control hyperglycaemia. Monotherapy with metformin or insulin secretagogues may fail
to sustain control after an initial reduction in glycemic levels. Thus, combining metformin with
other agents is frequently necessary. These analyses model the potential long-term economic and
health impact of using combination therapy to improve glycemic control.
Methods: An existing model that simulates the long-term course of type 2 diabetes in relation to
glycosylated haemoglobin (HbA1c) and post-prandial glucose (PPG) was used to compare the
combination of nateglinide with metformin to monotherapy with metformin. Complication rates
were estimated for major diabetes-related complications (macrovascular and microvascular) based
on existing epidemiologic studies and clinical trial data. Utilities and costs were estimated using data
collected in the United Kingdom Prospective Diabetes Study (UKPDS). Survival, life years gained
(LYG), quality-adjusted life years (QALY), complication rates and associated costs were estimated.
Costs were discounted at 6% and benefits at 1.5% per year.
Results: Combination therapy was predicted to reduce complication rates and associated costs
compared with metformin. Survival increased by 0.39 (0.32 discounted) and QALY by 0.46 years
(0.37 discounted) implying costs of £6,772 per discounted LYG and £5,609 per discounted QALY.
Sensitivity analyses showed the results to be consistent over broad ranges.
Conclusion: Although drug treatment costs are increased by combination therapy, this cost is
expected to be partially offset by a reduction in the costs of treating long-term diabetes
complications.
Background
Type 2 diabetes is a prevalent disease with complications
that cause substantial financial burden [1]. Improving gly-
cemic control can influence the prognosis for patients
with type 2 diabetes as it reduces the risk of developing
microvascular complications (nephropathy, neuropathy
and retinopathy) [2]. Recent guidelines from the National
Institute of Clinical Excellence (NICE) recommend the
initial use of diet and exercise and, when these fail to
maintain glycemic control, metformin should be
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prescribed [3]. Monotherapy with any treatment, how-
ever, is often unable to sustain target HbA1c levels of 6.5–
7.5% in the majority of patients. They are therefore
expected to require additional therapy within six years [4].
Sulphonylureas have been frequently used in combina-
tion with metformin, but are not always appropriate
choices as these may cause weight gain and increase the
risk of hypoglycaemia [3]. The development of newer
insulin secretagogues, such as nateglinide, provides physi-
cians with an alternative to sulphonylureas when selecting
the optimal combination of oral agents for an individual
patient. Nateglinide (120 mg three times per day) is
advantageous over other agents in that it helps to control
postprandial glucose (PPG) levels, along with glyco-
sylated hemoglobin, and also can be used in combination
with metformin (500 mg three times per day) [5]. The use
of combination therapy subsequent to the failure of mon-
otherapy helps some patients to achieve the recommend
levels of glycemic control. However, use of any combina-
tion is clearly also associated with an increased cost com-
pared with metformin as monotherapy.
The purpose of this study was to estimate the potential
long-term health and economic impact of adding nategli-
nide to metformin in order to improve glycemic control
and thereby reduce complication rates. Together with the
clinical data on the therapeutic efficacy of combination
therapy, these economic analyses facilitate assessment of
the long-term cost-effectiveness from the perspective of
the health care system, of using this combination to
achieve improved glycemic control.
Methods
Model framework
This model was developed to simulate the lifetime risk of
developing diabetes-related complications rates (microv-
ascular and macrovascular) in a cohort of patients diag-
nosed with type 2 diabetes [6,7] (Figure 1). In this
updated version of the model, both the level of HbA1c
(glycosylated haemoglobin) and two-hour postprandial
glucose (PPG) define the degree of glycemic control [8,9].
Each year of remaining life is simulated for all the patients
in the cohort and during each cycle, the patient is exposed
to the risks of developing each type of complication.
These risks are determined from the degree of glycemic
control, as well as other known risk factors, such as dura-
tion of diabetes.
The microvascular complications (nephropathy, retinop-
athy, and neuropathy) have several stages through which
each patient can progress. The most severe stages for the
microvascular complications are end stage renal disease,
blindness or amputations. The stages of a complication
are assumed irreversible – only progression to more severe
stages is possible. Complications such as hypoglycaemia
and foot ulcer were assumed to resolve in the course of
each cycle of one year. For the purpose of this model, mac-
rovascular complications (stroke and myocardial infarc-
tion) were considered as finite events, rather than
progressive conditions.
Each simulated patient had clinical characteristics that
were determined by the input distributions specified.
Using a Monte Carlo technique, each patient in the cohort
was assigned gender, race and age. The assignment of cho-
lesterol level, smoking status, body mass index and systo-
lic blood pressure was then determined using the
distributions and associations observed amongst patients
with type 2 diabetes [10-12].
For thirty annual cycles, the model checks each patient
who has survived to that point, and updates the age, dura-
tion of disease and HbA1c level. Over each cycle, the esti-
mated risks of developing a new complication or
progressing to the next stage of an established one are
assigned to each simulated patient in the cohort. During a
pre-model period of seven years, the patients were
allowed to accumulate complications but costs from man-
aging these complications are not considered in the
comparisons.
The model was assessed for face validity by clinical experts
and health authorities. Previous analyses using the model
have been evaluated by peer review [6-9]. Source data and
other independently obtained results were used as com-
parisons to determine predictive validity [2,13]. Model
results for relative risk over 10 years for all-cause mortality
and for microvascular disease and retinopathy at 12 years
were consistent with UKPDS patients in intensive and
conventional treatment groups.
Risk estimates
The risk of death in this updated model was linked to both
PPG and HbA1c levels. Weibull functions were derived
from the Diabetes Epidemiology: Collaborative Analysis
of Diagnostic Criteria in Europe (DECODE) study [14,15]
– and estimates were based on the patients' age, gender,
systolic blood pressure, total cholesterol, body mass
index, smoking status, and PPG level. As in the original
model, the risk of death was also assessed from the age-
and gender-dependent mortality for patients diagnosed
with type 2 diabetes [16], with an adjustment if nephrop-
athy develops [17,18]. The higher of these three death risk
estimates in each model cycle was applied.
The estimates for microvascular complications (nephrop-
athy, retinopathy, and neuropathy) were determined
from the available epidemiological studies [19-21] and
the risk gradients observed in the Diabetes Control andCost Effectiveness and Resource Allocation 2004, 2 http://www.resource-allocation.com/content/2/1/2
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Complications Trial (DCCT) were assumed to apply to
type 2 diabetes [22], an accepted assumption [23-25] con-
firmed by the UKPDS [2]. The risks of each microvascular
complication are estimated by adjusting each according to
the patient's HbA1c level at a specific point in time (risk =
1 - e -λ-t, where λ = λbHr
β, and Hr is the HbA1c value relative
to a standard and β is a complication-specific coefficient)
[16,26]. The base hazard for a complication depends on
factors such as duration of diabetes, race and for the retin-
opathy module, for example, also the probability of detec-
tion and treatment.
Evidence has recently been published that indicates PPG
is an independent predictor of the occurrence of macrov-
ascular complications, as well as of mortality [14,27,28].
In this updated model, the risk of stroke or myocardial
infarction was estimated using Weibull functions derived
from the DECODE study [15]. The risk equations derived
from the DECODE study include established risk factors
for macrovascular disease such as age, gender, systolic
blood pressure, total cholesterol, body mass index, smok-
ing status, as well as PPG level.
Costs
For each complication, the direct medical costs were esti-
mated for the immediate impact of the event (costs arising
in the year the event occurs) and the subsequent impact of
the complication (costs accrued in years subsequent to the
year of the event). Clarke et al combined resource use data
collected from the UKPDS with cost estimates for these
services, and published regression equations for estimat-
ing the cost of major complications [29]. The annual hos-
pital in-patient costs, and non-hospital costs (general
practioners, nurses, podiatrists, opticians, dieticians, hos-
pital outpatient clinics) were estimated using these regres-
sion equations for the event year and subsequent years. As
the inpatient costs were estimated for myocardial infarc-
tion, stroke, blindness, or an amputation. The inpatient
costs of less severe stages of these complications were not
included in these estimates the cost estimates are quite
conservative. All complication costs are expressed in 1999
Schematic representation of model (Reprinted with permission from Can J Diabetes Figure 1
Schematic representation of model (Reprinted with permission from Can J Diabetes. 2003; 27(1): 33–41).
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Great Britain Pounds (£1 GBP = $1.7 USD = €1.4 Euros).
It should be noted that the cost of end stage renal disease
was estimated based on data from 1996 [30]. We elected
not to inflate this cost, however, as the applicability of
general inflation rates to something as specialized as the
management of end stage renal disease is fraught with
inaccuracy and this was the most expensive complication
(£21,456 per year).
The drug treatment cost estimates conservatively assumed
full compliance with the treatment. The daily cost for met-
formin (1500 mg per day) was £0.07 [31], and £0.87 for
the combination of nateglinide (360 mg/day = £0.80)
with metformin (1500 mg per day) [31].
Analyses
The distributions of HbA1c and PPG at the beginning of
the model period, as well as the effects of each treatment
regimen were obtained from a clinical trial assessing the
efficacy of combining nateglinide (360 mg/day) with met-
formin (1500 mg per day) compared with metformin
alone [5] (Table 1). The mean HbA1c at baseline was 8.4%,
at the trial end point the HbA1c was reduced with both
metformin and for the combination (-0.8%, and -1.5%
respectively), as was the PPG level (-0.9, and -2.3
respectively).
After processing each cohort of 10,000 patients over thirty
years, the model provides estimates of the mean survival
time, the frequency of each type of complication, and the
mean accumulated complication and treatment costs per
patient. Survival time is also weighted by the quality of
life; the utility assigned depending on the complications
present. The utilities assigned were as follows; amputation
0.50, stroke 0.62, blindness 0.71 and myocardial infarc-
tion 0.73 [32], end stage renal disease 0.59 [33]. The cost
per life year gained (LYG) and cost per quality adjusted
life year (QALY) was determined. Consistent with NICE
recommendations, costs were discounted at 6% and ben-
efits at 1.5% [34]. Sensitivity analyses were conducted on
model parameters and uncertainty in the base case esti-
mates was examined using the bootstrap technique with
250 model replications, and 1000 re-samples from the
results of these simulations.
Results
Our analyses simulated a cohort of patients treated with
metformin and estimated the mean survival time to be
13.5 years. Over their lifetime, microvascular complica-
tions were frequent – retinopathy was the most common
affecting over a quarter of the patients, as well as foot
ulcers and microalbuminuria (Table 2). The model pre-
dicted mean lifetime discounted costs per patient of about
five thousand pounds (Table 3). Macrovascular disease
was common (Table 2) and accounted for about 40% of
the lifetime costs due to complications, with myocardial
infarction being the slightly larger component of the mac-
rovascular costs (63%). Amputation comprised one third
of the cost estimate for management of microvascular
complications.
Base case
The improvement in glycemic control, in terms of both
the HbA1c and the PPG, expected with the combination
nateglinide with metformin is estimated to increase sur-
vival on average 0.39 years per patient (0.32 discounted
years) or 0.46 (0.37 discounted) QALY (Table 3). Moreo-
ver, complications were expected to occur less frequently,
or at least progress more slowly (Table 2).
Combination therapy is expected to reduce the frequency
of complications and prolong survival, but also increase
the average costs by an average of £2,066 per patient. To
determine the impact of the nateglinide-metformin com-
bination on the cost of managing complications, the dif-
ference in mean cost between metformin alone and the
combination group was determined (Table 3). Thus, sav-
ings of £464 were estimated regarding the lifetime cost of
managing complications. These arise mainly from a
reduction in the costs of treating end stage renal disease
(72%) and neuropathy (19%). The increase in the treat-
ment costs due to combination therapy are therefore pre-
dicted to be partially offset by this reduction in the cost of
managing complications, leaving an increment of £2,066
in the lifetime costs per patient (Table 3). This translates
into a cost-effectiveness ratio of £6,772 (95%CI: £6,134
to 7,464) per additional discounted year of life, and
£5,609 per discounted QALY.
Table 1: Clinical characteristics of simulated cohort
Parameter Value
Age (years)
Mean 58
Range 29–88
Gender (% Female) 38%
Race
Caucasian 92%
Afro-Caribbean 4%
Asian 4%
Initial resulting HbA1c level (mean)
Metformin monotherapy 7.6%
Combination therapy 6.9%
HbA1c annual upward drift 0.15%Cost Effectiveness and Resource Allocation 2004, 2 http://www.resource-allocation.com/content/2/1/2
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Sensitivity analyses
The model inputs were varied to reflect different scenarios
and Table 4 shows the impact on the estimates. The degree
of upward drift of HbA1c and initial HbA1c were influential
parameters. If a population with higher glycemic levels at
baseline is modeled, a larger proportion of the cohort
develops severe complications on metformin alone. Vary-
ing the discount rate had a major effect on the cost-effec-
tiveness results.
Varying the efficacy of the combination of nateglinide and
metformin on PPG values had a minor effect, a 50%
reduction in efficacy led to a 3% increase in macrovascular
disease related costs. Varying the impact of the combina-
Table 2: Frequency of microvascular and macrovascular complications by treatment
Complication Metformin (/100 pt) Combination (/100 pt) Improvement
Absolute Relative (%)
Nephropathy
Microalbuminuria 21.1 18.1 3.0 14.2
Gross proteinuria 18.8 13.4 5.4 28.7
End stage renal disease 5.9 4.4 1.5 25.4
Retinopathy
Background retinopathy 30.7 23.7 7.0 22.7
Macular edema:
Detected 25.4 20.6 4.7 18.7
Photocoagulated 24.3 19.9 4.5 18.4
Proliferative retinopathy:
detected 12.3 7.9 4.5 36.3
photocoagulated 12.1 7.7 4.4 36.3
Blindness 9.4 8.0 1.4 14.9
Neuropathy
Foot ulcer 21.1 16.3 4.8 22.7
Neuropathy 12.7 9.6 3.2 24.8
1st Lower-extremity
amputation
9.0 7.5 1.5 16.5
2nd Lower-extremity
amputation
5.1 4.3 0.7 14.6
Macrovascular Disease
Myocardial infarction 15.0 14.6 0.4 2.4
Stroke 13.7 13.4 0.3 1.9
Table 3: Health benefits and costs for metformin and the combination of metformin with nateglinide
Metformin Combination Difference
Cumulative cost (mean per 
patient)
Complications £3,548 £3,084 £-464
Total £5,093 £7,159 £2,066
Survival (mean, years)
Life years (discounted) 13.5 (11.7) 13.9 (12.1) 0.39 (0.32)
Quality Adjusted (discounted) 12.2 (10.7) 12.6 (11.0) 0.46 (0.37)
Cost-effectiveness
Cost per LYG (discounted 
LYG)
£5,403 (6,772)
Cost per QALY (discounted 
QALY)
£4,500 (5,609)
LYG = Life Year Gained QALY = Quality Adjusted Life YearCost Effectiveness and Resource Allocation 2004, 2 http://www.resource-allocation.com/content/2/1/2
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tion of nateglinide and metformin treatment on HbA1c
values had a larger impact on the total cost predicted.
Decreasing the efficacy by 10%, or 25% led to total cost
increases of 3%, and 9%, respectively. Also a 10% increase
in efficacy led to a 4% decrease in costs.
Discussion
Improving glycemic control using combination therapy
will inevitably increase drug treatment costs when com-
pared with monotherapy. However, the reduction in
HbA1c and PPG levels when treating patients with type 2
diabetes with a combination of nateglinide and met-
formin has the potential to translate into reduced compli-
cation rates. Long term therefore, combination treatment
is likely to result in substantial offsets in overall costs.
Thus, the additional glycemic control is achieved at a rate
of £6,772 per year of additional life, an estimate generally
considered cost-effective [35].
These results are consistent with the evidence emerging
from the UK. Diabetes-related complications have been
shown in several UK studies to require expensive medical
interventions, frequently provided in a hospital inpatient
setting [36-39]. The UKPDS demonstrated that keeping
Table 4: Sensitivity analysis
Change in Outcome CER
Parameter Net Cost LYG QALY Cost/LYG Cost/QALY
Base values £2,066 0.32 0.37 £6,772 £5,609
Age (mean)
46.5 years £2,531 0.34 0.45 £7,476 £5,589
82.5 years £718 0.14 0.12 £5,303 £5,804
Cost of complications
+20% £1,973 0.32 0.37 £6,213 £5,357
-20% £2,159 0.32 0.37 £6,799 £5,861
Duration of disease 
before oral agent 
prescribed
5 years £2,101 0.27 0.33 £7,680 £6,320
10 years £1,971 0.31 0.35 £6,260 £5,553
Utilities
+20% £2,066 0.32 0.36 £6,506 £5,807
-20% £2,066 0.32 0.38 £6,506 £5,426
Race
100% Caucasian £2,105 0.31 0.36 £6,686 £5,771
HbA1c level
HbA1c before 
prescription = 9.4%
£1,782 0.37 0.42 £4,784 £4,287
Metformin = 8.6%
Combination = 7.9%
HbA1c before 
prescription = 7.9%
£2,184 0.28 0.34 £7,904 £6,516
Metformin = 7.1%
Combination = 6.4%
HbA1c upward drift
Metformin = 1.5%; 
Combination = 0%
£1,478 0.54 0.65 £2,761 £2,272
Metformin = 0%; 
Combination = 0%
£2,307 0.28 0.31 £8,336 £7,338
HbA1c drift delay
Metformin = 0 years; 
Combination = 1 year
£1,987 0.35 0.41 £5,715 £4,870
Discount
Cost = 3%; Benefit = 
3%
£2,420 0.26 0.30 £9,319 £8,058
Cost = 6%; Benefit = 
6%
£2,066 0.18 0.21 £11,369 £9,888
Cost = 6%; Benefit = 
0%
£2,066 0.39 0.46 £5,237 £4,500Cost Effectiveness and Resource Allocation 2004, 2 http://www.resource-allocation.com/content/2/1/2
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glucose levels near normal decreased the incidence of
microvascular complications over ten years [40]. In addi-
tion, cost-effectiveness analyses based on the UKPDS
results indicate the costs of managing complications
would be expected to be reduced, [41,42] and, specifi-
cally, intensive blood glucose control with metformin is
predicted to result in lower complications costs amongst
overweight patients [42]. The DCCT results showed
improved glycemic control can lower microvascular com-
plication rates in patients with type 1 diabetes, and one
key assumption of this model is that these rates also apply
to type 2 diabetes. This assumption was demonstrated to
be tenable by similar findings in the UKPDS [2,3]. This
model predicts comparable results to those of the UKPDS
patients in the intensive and conventional treatment
groups in terms of relative risk over ten years for microv-
ascular disease or retinopathy at 12 years.
The economic implications of combination therapy
depend to some extent on the characteristics of the cohort
analyzed. For example, the sensitivity analyses illustrate
that greater savings are predicted for patients diagnosed
when they are young, with longer duration of disease and
poorer glycemic control initially. These characteristics
tend to identify patients at higher risk of developing com-
plications later on.
Macrovascular disease is predicted to be the major com-
ponent of the costs accounting for over one third of the
costs accrued over a lifetime from managing diabetes
related complications. This is of particular importance as
these complications tend to arise earlier in the course of
the disease than those that are microvascular in nature,
and are the leading cause of death [43,44]. Thus, from
both the clinical and economic perspectives, it is impor-
tant that in addition to glycemic control, any risk factors
for cardiovascular disease that are known to be modifiable
are managed such as smoking cessation, reducing obesity,
high blood pressure and hypercholesterolaemia [3,45].
The equations developed for predicting the risk of stroke
and of myocardial infarction included the PPG level.
These predictions are based on the results of the DECODE
study that investigated the prevalence of macrovascular
disease and mortality in Europe [14,28,46]. Thus, the
assumption in the model that reducing PPG levels will
reduce the risk of macrovascular disease remains to be
proven conclusively[3,47].
The long-term predictions were based on the efficacy of
combining nateglinide with metformin demonstrated in
clinical trials [5]. Even though these analyses were based
on the efficacy observed in a randomized, controlled trial,
it was necessary to make some assumptions about long-
term glycemic control. Given the lack of specific data on
the combination over longer timeframes, it was assumed
that after the initial improvement in glycemic control, the
HbA1c would begin to drift upward as it did with met-
formin and other hypo glycemic agents employed in the
UKPDS [4,48]. This is a conservative assumption as it is
quite possible that with the combination there will be a
slower, or at least delayed, upward drift.
The cost inputs for these economic analyses were limited
to only the most severe stages of the complications. This
was done in order to accord with the estimates' source, the
UKPDS. The costs also did not include the less severe
stages of the complications (such as gross proteinuria,
foot ulcers or photocoagulation). Similarly, the macrovas-
cular costs do not include the management of milder con-
ditions such as angina or transient ischaemic attacks.
Thus, the cost estimates are quite conservative implying
that the savings are underestimated.
Conclusion
In conclusion, prescribing the combination of nateglinide
and metformin for patients who are not maintaining
good glycemic control on monotherapy alone should be
cost-effective, as the combination is expected to reduce
the rates of diabetes-related complications at an accepta-
ble additional cost. Long-term data are needed to confirm
these predictions.
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